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ON THE DIFFERENTIAL CYTOTOXICITY
OF ACTINOMYCIN D
INTRODUCTION
Although actinomycin D (AMD) inhibits tran-
scription in nearly all animal cells in conequences
of its binding to DNA (18, 36), certain cell types,
e.g. intestinal, lymphocytic, and haematopoietic,
are much more susceptible to cytotoxic injury by
this drug in vivo (44). The carcinostatic action of
AMD on such susceptible tumors as renal or
genital embryonal carcinomas also depends upon
its selective cytocidal toxicity. Some of the vulner-
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ABSTRACT
Actinomycin D (AMD) at concentrations that inhibit cellular RNA synthesis by 85% or
more causes an acute phase of lethal cell degeneration in HeLa cultures beginning as early
as 3 hr after drug exposure, resulting in the nearly complete loss of viable cells by 12 hr .
The loss of cells during this acute phase of lethality is closely dose dependent . Vero, W138,
or L cells are not susceptible to this early acute cyto-intoxication by AMD, and may begin
to die only after 1-2 days. Differential susceptibility to acute cyto-intoxication by AMD, or
other inhibitors of RNA synthesis (daunomycin or nogalamycin), among different types of
cultured cells is analogous to that observed in vivo in certain tissues and tumors, and cannot
be accounted for by differences in the effect of AMD on RNA, DNA, or protein syntheses,
or by the over-all loss of preformed RNA . Actinomycin D in a dose that inhibits RNA
synthesis causes an equivalent loss of the prelabeled RNA in all the cell types studied . In-
hibition of protein synthesis with streptovitacin A or of DNA synthesis with hydroxyurea
does not cause acute lethal injury in HeLa cells as does inhibition of RNA synthesis . Further-
more, since Vero or L cells divide at about the same rate as HeLa cells, no correlation can
be drawn between the rate of cell proliferation and susceptibility to the cytotoxicity of AMD.
Susceptibile cells are most vulnerable to intoxication by AMD in the G I-S interphase or
early S phase. Inhibition of protein synthesis (which protects cells against damage by other
agents affecting DNA) does not protect against AMD-induced injury . Although HeLa cells
bind more AMD at a given dose than Vero or L cells, the latter cell types, given higher doses,
can be made to bind proportionally more AMD without succumbing to acute cyto-intoxica-
tion. It is suggested that the differential susceptibility of these cell types to acute poisoning
by AMD may reflect differences among various cells in the function or stability of certain
RNA species not directly involved in translation whose presence is vital to cells . In HeLa
cells, these critical species of RNA are presumed to have a short half-life .
able tissues, especially intestinal crypt epithelium,
suffer acute degeneration as early as 4 hr after
injection of a single dose of AMD, while other
susceptible tissues (including both proliferating
systems as well as stationary cells such as dorsal
root ganglion and salivary acinar epithelium)
manifest toxic damage only much later (19, 44) . We
have observed that among different cell types in
culture there is an analogous selective cytotoxicity
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scription) to that described in vivo (13). A single
(pulse) dose of AMD, daunomycin, or nogala-
mycin that suppresses RNA synthesis by 85
kills a large proportion of the HeLa population,
but not W138, Vero, or L cells, in an acute early
phase beginning about 3 hr after exposure. Smaller
numbers of W138 and L cells may succumb only
much later, and Vero cells are relatively even
more resistant. AMD inhibits RNA synthesis in all
of these cells; and although susceptibility to cyto-
static agents has sometimes been correlated with
rate of cell proliferation (3), all of the cell lines
that we have studied have similar generation times
and cell cycles. Nevertheless they exhibit marked
differences in their susceptibility to acute intoxica-
tion by AMD.
Definitive studies have been published on the
ultimate effects of AMD on the potential for
proliferation of particular cell lines in terms of
reproductive survival, such as have been widely
employed in assessing the effects of radiation or
radiomimetic and other cytostatic agents in vitro
(2, 8-10, 23). Such information does not distin-
guish between acute or delayed cell degeneration,
prolonged "metabolic" survival with inability to
divide, proliferative latency with eventual re-
covery, and arrest after one or more divisions . In
this study we are concerned with acute and sub-
acute lethal toxic cell degeneration, a form of early
premitotic cytocidal injury analogous to the "in-
terphase death" observed in vitro after high doses
of radiation (14) .
The early acute degeneration of HeLa is prob-
ably the same process as that which occurs in
intestinal crypt epithelium, lymphocytes, and
probably embryonal carcinoma. The relative re-
sistance of Vero cells is like that of hepatocytes,
dimethylbenzanthracene (DMBA) transplantable
tumors, and some other tissues (44) which, like
Vero cells, can survive high single (pulse) doses
of AMD fatal to susceptible cells. The reasons for
the differential susceptibility to cytolysis by AMD
of these various tissue, tumor, and cultured cell
types are mostly not understood . We have in-
vestigated the basis of the selective acute cyto-
toxicity of AMD, and some aspects of resistance in
cell culture, by comparing the effects of AMD in
different cell lines in relation to growth rate, age
in the cell cycle, inhibition of macromolecule
synthesis, depletion of RNA, and binding of
AMD14C. It has also been our object to study the
mechanism of the acute cell injury effected by
this agent, important in experiment and in therapy,
many of the effects of which on biosynthesis are
already well known.
MATERIALS AND METHODS
Monolayer cultures of HeLa cells (CCL 2, Ameri-
can Type Culture Collection), HeLa S3 cells, L cells
(a subline of NCTC clone 929 mouse cells), W138
cells in 18th-26th passage, and Vero cells (a con-
tinuous cell line derived from African green monkey
kidney) were grown in milk dilution bottles at 37 °C
in Eagle's minimal essential medium (MEM) sup-
plemented with 10% (v/v) fetal or newborn calf
serum, 75 units/ml penicillin, and 75 pg/ml strepto-
mycin, in an atmosphere of 5% CO in air. The
cultures were periodically tested for mycoplasma with
negative results. Eagle's MEM was modified in some
experiments by replacing bicarbonate with 0.035 M
N-2-hydroxyethylpiperazine-N'-2 ethane sulfonic acid
(HEPES) (45). All experiments were performed on
cultures in exponential growth, at least 18 hr after
passage. Either 30-m1 flasks or 60-mm Petri dishes
(Falcon Plastics Div. of B-D Laboratories, Inc., Los
Angeles, Calif.) containing from 106 to 2 X 106 cells
each were used in the cell enumeration and radio-
active labeling studies. Cytological examinations,
including the mitotic and moribundity indices and
radioautography, were performed with cells growing
on coverglasses in Leighton tubes or in 35-mm plastic
Petri dishes. All experiments were performed in
duplicate.
Actinomycin D (Merck, Sharp & Dohme, West
Point, Pa.), daunomycin (National Cancer Institute),
and nogalamycin (Upjohn Co., Kalamazoo, Mich.)
were dissolved in dimethyl sulfoxide (10 mg/ml), and
a stock solution (100 jug/ml) was prepared by dilu-
tion with distilled water. The exact concentration of
the AMD stock solution was determined by reading
the optical density at 441 nm (e = 25.7 X 101). Direct
exposure of antibiotic solutions to light was avoided
at all times. The stock solutions were diluted with
fresh growth medium to the desired concentration
and applied in a volume of 2 ml/10 6 cells. Unless
otherwise stated, the exposure period to AMD was
1 hr, followed by rinsing and refeeding of the cultures
with fresh drug-free medium ; the cultures were refed
again 3 hr later to remove the AMD that had diffused
back into the medium either from the cells or from
the plastic surface (10).
The number of viable cells was determined in
replicate cultures by the dye exclusion method (24) .
After a 10 min incubation in 0.1 % trypan blue, the
cell sheet was rinsed twice with Earle's balanced salt
solution (EBSS), detached by incubation in 0 .25%
trypsin in EBSS containing 0.15% Versene (Dow
Chemical Co., Midland, Mich.), and dispersed to a
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747single cell suspension . The viable, or unstained, cells
were counted in a hemacytometer . Some experiments
were performed using a Coulter electronic particle
counter (Model B). The number of mitotic cells de-
tached by rinsing represented less than 1 % of the total
cell population and was considered insignificant in
evaluating the number of viable cells.
RNA synthesis or degradation was measured by the
amount of incorporated 14C-labeled uridine (55.2
mCi/mmole, New England Nuclear Corp ., Boston,
Mass.) present in the acid-insoluble cell residue. The
label (0.1-0.3 ACi/ml) was applied for the times
stated in the Results in fresh growth medium con-
taining 2 X 10-5 M thymidine and deoxycytidine to
prevent incorporation into DNA. After removing the
excess label and rinsing with EBSS, the cells were
detached and suspended as described for cell enumer-
ation, and a known number of cells were precipitated
and extracted for 10 min with cold 5% trichloroacetic
acid (TCA), the precipitates were collected and
washed on membrane filters (Bac-T-Flex No. B-6,
Schleicher & Schnell, Inc., Keene, N. H.), dried,
and counted in a toluene base scintillant (Omnifluor,
Pilot Chemicals Inc., Div., Watertown, Mass.) with
a Packard Liquid Scintillation Spectrometer at an
efficiency near 80%. The data are expressed without
quench correction or background subtraction .
The binding of 14C-labeled AMD (11.4 mCi/
mmole, New England Nuclear Corp.) was assayed as
above with exceptions as detailed in the Results . In
addition to collecting TCA-extracted cells on filters,
duplicate samples were dissolved in NCS (Amersham-
Searle Corp., Des Plains, Ill.) without TCA-extrac-
tion. These different methods of sample preparation
gave equivalent amounts of radioactivity. This finding
differs from those of Magee and Miller (22), who
found 23% of the cell-associated AMD-3H susceptible
to methanol and TCA extraction (15% was extracted
by methanol alone) and of Bacchetti and Whitmore
(2), who reported that washing with TCA resulted in
a dissociation of DNA-AMD-3H complexes. Bac-
chetti and Whitmore (2) also found high background
radioactivity when using AMD- 3H, while in the
experiments described here with AMD- 14C the back-
ground radioactivity was negligible .
Moribundity indices were performed on cover-
glass cultures that had been given 1 .0 jCi/ml of
thymidine-3H (14 Ci/mmole, Schwartz Bio Research
Inc., Orangeburg, N. Y.) for 1 hr during the AMD
treatment and fixed in cold methanol at hourly
intervals. After extraction with cold 5% TCA, the
cover glasses were mounted on clean glass slides,
dipped in K-5 emulsion (Illford Ltd., Ilford, Essex,
England) and exposed for 1 wk at 4°C. After de-
velopment the cells were stained with azure B to
differentiate viable from moribund cells . Mitotic
indices were performed on formalin-fixed cells stained
by the Feulgen reaction. Cultures were synchronized
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at the beginning of S phase by applying two consecu-
tive thymidine (5.0 mm) treatments (25).
RESULTS
Dose-Dependent Degeneration of HeLa Cells;
a Comparison with Other Cell Types
Actinomycin D, at concentrations commonly
employed to inhibit RNA synthesis in cell cultures
(1-10 µg/ml), is acutely cytocidal to HeLa cells.
As shown in Fig. 1, the continuous exposure of
HeLa cells to concentrations of AMD greater than
0.1 µg/ml causes the detachment from monolayer
and the lysis of about 75-800 /0 of the cells within
12 hr. The injured or moribund cells, which are in
interphase and are easily identified by a distinc-
tive kind of pyknosis, begin to appear only after 2
hr and then accumulate rapidly during the next
6-8 hr. With continuous exposure to lower doses
(between 0.1 and 0.01 µg/ml), the acute phase of
cell degeneration is delayed. When AMD is ad-
ministered for I hr, concentrations greater than
0.35 µg/ml cause an acute phase of cell destruc-
tion; and the fraction of the population that
survives this acute phase is inversely related to the
drug concentration (Fig. 2). A drug concentra-
tion, 0.35 ug/ml, that is not acutely cytotoxic
when administered for 1 hr becomes so when ad-
ministered for 2 hr (Fig. 2, broken line). Thus, the
extent of degeneration in HeLa culture during the
acutely lethal phase is closely dose dependent for
drug concentrations higher than 0.01 ug/ml but
lower than 2.5,ug/ml. AMD concentrations in ex-
cess of 2.5 µg/ml cause a maximum loss of HeLa
cells and do not increase the rate at which cells are
detached from monolayer. Pyknotic cells are never
seen in HeLa culture sooner than 2 hr, even after
treatment with high drug concentrations .
HeLa S3 cells are a little more resistant to early
acute injury induced by AMD than wild-type
HeLa cells, in that they do not begin to degenerate
until 6-8 hr after the addition of AMD (Fig . 3).
In contrast to HeLa cells, Vero, W138, or L cells
are not susceptible to early acute cell killing by
AMD. Fig. 3 shows that W138 and L cells treated
for 1 hr with 2.5 µg/ml are not killed during the
12 hr in which 75-80% of the HeLa cells are
destroyed by this dose, while Vero cells con-
tinuously treated with 10 µg/ml of AMD do not
succumb to acute lethal injury. These doses ef-
fectively abolish 95% or more of the RNA synthe-
sis in all of these cell types. Other inhibitors of
RNA synthesis are also acutely lethal to HeLaComparison of the Inhibition of RNA
Synthesis by AMD in Different Cell Lines
To determine whether there is a direct or
immediate relation between the suppression
cells. As shown in Fig. 4, continuous exposure to
daunomycin (10 µg/ml) or nogalamycin (10 µg/
ml) results in an equivalent loss of HeLa cells
from monolayer, and the appearance of the in-
jured cells is similar to that of cells acutely injured
by AMD. Vero cells are as resistant to these drugs
as they are to AMD and do not succumb during
an early acute phase of lethality.
The early acute form of cyto-intoxication is ob-
served only in HeLa cells, but smaller numbers of
Vero, W138, and L cells eventually succumb to
delayed toxic injury by AMD, beginning after
12-18 hr (Fig. 3). This delayed form of lethality
also occurs in HeLa cultures continuously exposed
to lower concentrations of AMD. Thus, only HeLa
cells undergo an early accelerated phase of cell
killing after high cytocidal doses of AMD to which
other cell lines succumb only much later if at all .
an
of
Hours after AMD
FIGURE 1 The effect of various concentrations of actinomycin D on the number of surviving HeLa cells
in monolayer culture. AMD was given at time 0, and the number of adherent living cells was counted at
intervals thereafter as described in Methods . 0.01 µg ml, --IS-; 0.05 µg/ml, -A-; 0.10 µg/ml, -0-;
0.50 µg/ml, -X-; 1.0 µg/ml, -o-; and 5.0 µg/ml, -O-
RNA synthesis and the early occurrence of
lethality, RNA synthesis, i.e. incorporation of
radio-uridine into the acid-insoluble cell residue,
was measured during or after treatment with vari-
ous doses of AMD. Table I and Fig. 5 show that a
range of drug concentrations between 0.1 and 2.5
µg/ml inhibits RNA synthesis in HeLa cells by
85% or more by 1 hr. Although RNA synthesis
eventually returns in the surviving cells after re-
moval of AMD, at a rate inversely proportionate
to dose, it remains at a very low level for at least
6 hr, even after treatment with sublethal doses
(between 0.1 and 0.5µg/ml administered for 1 hr).
Since early acute lethality occurs in HeLa cells
only after doses of AMD (or other RNA synthesis
inhibitors) that suppress 85% or more of over-all
RNA synthesis, it would appear that acute cyto-
intoxication results from the near complete inhibi-
tion of RNA syntheis. If early acute lethality in
HeLa cells is due to inhibition of RNA synthesis,
only the final 10-15 % of RNA synthesis remaining
after lower nontoxic doses of AMD would seem to
be implicated in acute cyto-intoxication . HeLa
cells withstand inhibition of up to 85% of over-all
S. G. SAWICKI AND G. C. GODMAN Cytotoxicity of Actinomycin D
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FIGURE 2 Dose-dependent acute killing of HeLa cells
by AMD. Various concentrations of AMD were given
at time 0 to HeLa cells for 1 hr or for 2 hr, followed by
rinsing and refeeding with drug-free medium. The
cultures were refed again 3 hr later to remove any
AMD that had diffused out of the cells . The adherent
viable cells were counted at intervals as described in
Methods. 10 µg/ml, -0-; 2.5 µg/ml, -0-; 0.6 µg/
ml, -S--; 0.5 µg/ml, -C-; and 0.35 µg/ml, -0-;
0.35 µg/ml, . . . 0 • • • .
RNA synthesis without early acute lethality ; but
as RNA synthesis is further depressed either with
higher drug concentrations or with longer exposure
periods, acute cell death begins to occur after a
latent interval whose duration is proportional to
dose. Doses of AMD in excess of those that com-
pletely block RNA synthesis do not increase the
extent of lethal injury (Fig . 1) nor do they shorten
the latent interval of at least 2 hr before the ap-
pearance of pyknotic cells . Thus, once RNA
synthesis is inhibited by more than 85% . HeLa
cells begin to undergo an acute degenerative pro-
cess beginning 2-3 hr after drug treatment .
Vero, W138, and L cells suffer comparable in-
hibition of RNA synthesis (more than 90%0 after
1 hr of 2.5 µg/ml) (Table I). Recovery of RNA
synthesis in L cells begins about 18 hr after the
removal of a 1 hr dose of 5µg/ml of AMD, while
Vero cells regain 50% of their capacity to synthe-
o
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FIGURE 3 A comparison of acute AMD toxicity in
HeLa, HeLa S3, Vero, W138, and L cells . A dose of
2.5 µg/ml of AMD was given for 1 hr to HeLa (-(D-),
HeLa S3 WI38 (-X-), or L cells (-A-),
and a dose of 10 µg/ml to Vero cells for 1 hr (-fl-)
or for 24 hr (- -). AMD was administered as
described in Fig. 2. The adherent living cells were
counted as described in Methods. Note that although
Vero cells resume RNA synthesis within 6 hr after a
pulse dose of 10 µg/ml for 1 hr (Table I), they did not
resume multiplication until after 72 hr.
100
25
3
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FIGURE 4 The rate of acute cell killing in HeLa cul-
tures continuously exposed to actinomycin D (0.5 )ug/
ml, -0-), daunomycin (10 µg/ml, -X-), or nogala-
mycin (10 µg/ml, -o-). The drugs were given at
time 0 and the number of adherent viable cells was
counted at 3, 6, 12, and 24 hr.TABLE I
Inhibition of RNA Synthesis in HeLa, Vero, WI38, and L Cells Treated with AMD
size RNA by 3 hr after removal of 10 µg/ml, and
by 24 hr uridine I4C incorporation is near the
control rate. For this reason it is necessary to ex-
pose Vero cells continuously to AMD when com-
paring Vero to HeLa cells with respect to acute
lethality and suppression of RNA synthesis .
Although Vero cells reinstate RNA synthesis,
within 6 hr after removal of a 1 or a 4 hr pulse
dose of AMD (10 µg/ml), cell division does not
resume until after 48-72 hr. W138 cells do not
recover their capacity to synthesize RNA after
removal of 2.5 µg/ml. Thus, RNA synthesis is
completely inhibited by AMD in all the cell
types studied, but of these only HeLa undergoes
acute degeneration within a few hours after in-
hibition of RNA synthesis . The other cell types
remain viable in monolayer for at least 12 hr or
The cultures were incubated for 20 min in uridine 14C-containing medium that was
drug-free at intervals after exposure to various doses of AMD . The radioactivity in the
acid-insoluble cell precipitate was assayed as described in Methods . In other experi-
ments (to be reported elsewhere), RNA synthesis in Vero returns to control levels by
4 hr after removal of a 1 hr or a 4 hr pulse dose of AMD (10,ug/ml) .
more usually some days longer, before finally suc-
cumbing to cyto-intoxication by transcription-
inhibiting doses of AMD.
Therefore, HeLa cells are uniquely susceptible
to early acute injury resulting from complete in-
hibition of RNA synthesis, while some other cell
types, although suffering comparable inhibition of
RNA synthesis, are not susceptible to this early
cell degeneration.
Loss of Cellular RNA
The possibility was examined that a greater loss
of RNA occurs in HeLa cells after acutely cyto-
toxic concentrations of AMD (but not with non-
cytotoxic concentrations), and that this loss is
somehow responsible for the special susceptibility
S. G. SAWICKI AND G . C. GODMAN Cytotoxicity of Actinomycin D
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Cell type jug AMD/ml
Hr of
exposure
Hr after
AMD removal cpm/l0s cells % of control
HeLa Control 1800 100
0.05 1 1050 58
1 1 965 54
1 2 740 41
0 .10 1 0 250 14
1 1 445 25
1 2 600 30
0 .50 1 0 85 5
1 1 115 6
1 2 125 7
1 .00 1 0 85 5
2 .50 1 0 40 3
W138 Control 630 100
2 .5 1 0 25 4
1 23 20 3
L cells Control 2400 100
2 .5 1 0 320 12
5 .0 1 0 150 6
1 23 550 22
Vero Control 2400 100
10 .0 1 0 60 3
1 3 1200 50
1 23 2000 83
1 .0 1 0 230 10
3 0 240 10
24 0 260 11752
TABLE 11
The loss of RNA from Cultures after Exposure
to AMD
Cultures were prelabeled with uridine-14C for I hr
(nuclear RNA) or for 12 hr (cytoplasmic RNA),
before addition of AMD ; the radioactivity of the
acid-insoluble residue was determined 1, 2, and
3 hr after treatment with AMD as described in
Methods.
5-
E
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1
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of HeLa cells to early acute injury as compared
with Vero and W138 cells. The cellular RNA was
labeled by means of a 1 hr pulse with uridine 14C
(0.2 pCi/ml) given either 1 hr ("nuclear" RNA)
or 12 hr ("cytoplasmic" RNA) before the addi-
tion of various concentrations of AMD . 1, 2, and 3
hr after the addition of AMD, the cells were col-
lected and the radioactivity in the acid-insoluble
cell precipitate was determined . Cytoplasmic RNA
is lost to the same extent (10% after 3 hr) after
treatment of HeLa cells with 0 .05, 0.5, and 5 µg/
ml of AMD and of W138 cells with 2 .5 µg/ml
(Table II) . The decay of the rapidly labeled
nuclear RNA is shown in Table II : there is a
nearly equivalent loss of label (RNA) after a
treatment of HeLa cells with 0.05, 0.5, 1 .0, 2.5,
and 5 µg/ml as with 10 µg/ml given to Vero cells
and 2.5 ig/ml given to W138 cells . Exposure to
lower drug concentrations results in somewhat
smaller loss of RNA (Table II) ; this probably
reflects both the slower rate of inhibition and the
incomplete suppression of RNA synthesis caused
by these lower doses (Fig. 5). The decay of pre-
labeled RNA observed after AMD administration
is unlikely to be the factor primarily responsible
Control
20
	
30
Minutes after AMD/Uridine- 14C addition
FIGURE 5 The dependence of the rate of' suppression of RNA synthesis on the concentration of AMD.
Various concentrations of AMD (given as micrograms per milliliter on graph) together with 19C-labeled
uridine (0.3 sCi/m1) were given to HeLa cells at time 0 . and the amount of radioactivity in the acid-
insoluble cell precipitate was determined at intervals as described in Methods .
40
% of uridine-14C remaining in acid-insol-
uble fraction at times after
AMD addition
Nuclear RNA
Cytoplasmic
RNA
Cell type Dose 1 hr 2 hr 3 hr 1 hr 3 hr
µg AMD/ml
HeLa 0 .05 63 60 62 95 90
0 .50 56 55 53 94 90
1 .00 53 52 53
2 .50 52 49 48
5 .00 48 47 44 92 90
Vero 10 .0 52 48 46
W138 2 .50 52 85for the acute degeneration of HeLa cells since an
equivalent loss of prelabeled RNA occurs in W138
and Vero cells and especially because a dose of
AMD that immediately reduces RNA synthesis
causes a nearly equivalent loss of prelabeled RNA
of HeLa cells but not an equivalent amount of
acute lethality (Figs. 1 and 2) .
Effect of Protein Synthesis
Is the acute cyto-intoxication of AMD to HeLa
cells due to a dose-dependent inhibition of protein
synthesis? Any dose of AMD that inhibits RNA
synthesis by more than 85% also reduces protein
synthesis by about 50% at 4 hr after drug treat-
ment. (Thereafter, it becomes difficult to assess
protein synthesis because of the variable numbers
of dead cells that begin to accumulate in HeLa
cultures.) However, inhibition of protein synthesis
by certain inhibitors is not acutely cytotoxic to
HeLa cells. Less than 20% of a HeLa culture is
killed at 12 hr after the virtually immediate and
complete stoppage of protein synthesis by strepto-
vitacin A (10 µg/ml), whereas a 1 hr exposure to
2.5 µg/ml of AMD kills 75% of a HeLa culture by
12 hr. In contrast to the protective effect of in-
hibitors of protein synthesis against injury caused
by irradiation or radiomimetic agents, the addition
of streptovitacin A (IO ug/mI) before, during, and
after the administration of AMD (2.5 µg/ml)
augments the early fatal injury to HeLa cells. By
8 hr no viable cells are left after this treatment .
Binding and Retention of AMD-14C
Is the early vulnerability of HeLa cells related
to a difference in the amount of drug taken up and
retained by these cells as compared with the other
cell types? This was assessed by determining the
amount of AMD14C bound into the acid-insoluble
cell residues. The AMD-14C retained in the cells
extracted with cold TCA is exclusively nuclear ; in
a subsequent report it will be shown that it is
bound only in chromatin and is extractible by
treatment with DNase. Fig. 6 A shows that HeLa
cells bind more AMD than Vero or L cells during
a 4 hr incubation with 1 .0 µg/mI. Fig. 6 A also
shows that HeLa cells bind AMD 14C at a high
rate for 2 hr, after which time the rate of uptake
slows considerably ; in L cells the rate of AMD
binding proceeds linearly for 3 hr before decreas-
ing; in Vero cells no further increase in the
amount of AMD bound per cell is observed after
1 hr. However, the data plotted in Fig . 6 B il-
lustrate that when these cell types are exposed to a
higher AMD concentration (2.5 and 10 Mg/ml for
1 hr) they can all bind more AMD per cell than
when given a lower concentration (Fig . 6 A, 1 .0
µg/ml) for a longer time. Therefore, the amount of
AMD bound per cell is directly proportional to the
drug concentration and, at a given concentration,
is only proportional to the length of the exposure
period for 1, 2, or 3 hr depending on the cell type .
Vero cells bind more AMD when treated with
10 ug/ml than HeLa treated with 2.5 µg/ml
(Fig. 6 B). Following the removal of AMD after
I hr, HeLa cells and L cells retain the AMD
longer than Vero cells. The accelerated diffusion
of AMD from Vero cells, after a 1 hr exposure to
AMD, appears to be correlated with the rapid
recovery of RNA synthesis in these cells (Table I) .
Vero cells treated with 10 µg/ml for 24 hr to en-
sure drug retention and continued suppression of
RNA synthesis do not show an acute phase of cell
killing even though they have taken up more AMD
than HeLa cells treated with cytocidal doses
(1-2.5 yg/ml). Thus, the vulnerability or resist-
ance of various cell lines to acute injury is not
entirely determined by the amount of AMD taken
up or retained by the cells. The dose dependence
of acute killing of HeLa cells may be correlated
with the amount of AMD maximally bound .
However, acute cell killing of HeLa cells follows
several hours after exposure to AMD for 1 hr and
occurs after more than half of the drug has dif-
fused out of the cell and has been removed by
washing and refeeding. Acute killing of HeLa
cells is dose dependent, and can be correlated with
the amount of AMD maximally bound, only in
that dose range within which there is some varia-
tion in the response of RNA synthesis to inhibition
by AMD. Doses exceeding those that maximally
inhibit RNA synthesis do not augment acute
killing, even though more AMD is bound in the
cell proportionally with higher drug concentra-
tions. Also, acute killing of HeLa cells follows
several hours after a 1 hr exposure to AMD, and
occurs after more than half of the drug has dif-
fused out of the cell and has been removed by
washing and refeeding. Vero, W138, and L cells
do not succumb to early killing even when con-
tinuously exposed to high concentrations of AMD
at which doses they bind more AMD than HeLa
cells. Vero cells are resistant to the more delayed
form of lethal injury that occurs in all of the other
S. G. SAWICKI AND G. C. GODMAN Cytotoxicity of Actinomycin D
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4
Hours after addition of AMD-'"C
FIGURE 6 Binding and retention of 14C-labeled AMD. AMD-14C was given to HeLa (O), Vero (0),
or L cells (A) for 4 hr (A) or for 1 hr followed by rinsing and refeeding with drug-free medium (B). The
radioactivity in the acid-insoluble cell precipitate was assayed at hourly intervals as described in Methods .
Fig. 6, A: A comparison of the amount of AMD- 14C bound and retained during a continuous 4 hr ex-
posure to 1 µg/ml. Fig. 6, B : A comparison of the amount of AMD-14C bound and retained after a 1 hr
exposure to ?.5 jsg/ml (	) or 10 µg/ml ( ) . The AMD-14C was given at 0 hr and removed at 1 hr .
cell types examined when RNA synthesis is kept
	
TABLE III
depressed, not because they bind less AMD but
	
Vulnerability of HeLa in DNA Synthesis (S
because they excrete AMD more rapidly than
	
Phase) to AMD
other cell types. This basis for the relative resistance
of Vero cells to AMD will be further explained in a
subsequent communication.
HeLa cultures, synchronized by two successive
thymidine treatments and given AMD 14C im-
mediately after (in early S) or 10 hr after removal
of the second block (in G 2-M), bind 10% and 60%
more AMD-14C, respectively, than unsynchronized
cultures. If acute killing were directly related to
the amount of D bound per c
, c s n l l 2
would be preferentially affected.
Cell Cycle and DNA Synthesis
Does a correlation exist between the position
of HeLa cells in the division cycle and suscep-
tibility to early acute killing by AMD? This
question was examined in two ways : (a) by de-
termining if the cells dying during the phase of
acute lethality are located in a particular phase of
the cell cycle while exposed to AMD, and (b)
by determining whether different rates of acute
cell killing occurred in synchronized cultures
treated with AMD while in different phases of the
cell cycle. HeLa cells in DNA synthesis (S) were
labeled with thymidine 1H (1 .0 sCi/ml) for 1
hr during a 1 hr AMD (1 .25 µg/ml) treatment,
HeLa monolayers were labeled with TdR during
treatment with AMD (1 .25µg/ml) for 1 hr, and were
fixed at 1, 4, and 6 hr after addition of AMD as
detcribed in Methods. Radioautograms were scored
to determine number of labeled cells per thousand.
and the cultures were fixed at intervals after the
combined labeling and AMD treatment. The
viable and moribund cells were scored in radio-
autograms as labeled or unlabeled, i .e. cells in S
or in some other phase of the cell cycle while AMD
was administered. Table III shows that nearly
all of the moribund cells which accumulate at 6
hr are derived from the population of cells that
were synthesizing DNA during exposure to AMD,
while the cells that were not in S during exposure
to AMD constitute the viable fraction . Hence, the
population of HeLa cells most susceptible to being
Viable cells Moribund cells
Time Labeled Unlabeled Labeled Unlabeled
Control 1 hr 560 440 0 0
AMD 1 hr 554 446 0 0
4 hr 522 411 24 43
6 hr 288 431 234 47TABLE IV
Relative Susceptibility of HeLa and of Vero Cells to Cytocidal Effects of AMD after
Synchronization with Thymidine
killed during the early acute phase of AMD-
induced lethality are those in S during the ex-
posure period. A 1 hr AMD dose of 2 .5 ug/ml
was administered to thymidine-synchronized HeLa
cells at various times after the removal of the
second thymidine block, and the number of viable
cells was counted at intervals thereafter. As shown
in Table IV, when this dose is applied to cells in
S, i.e. 2 hr after removal of thymidine, 46% and
90% of the population are killed by 6 and 12 hr,
respectively, as compared to 15 0 / 0 and 75% killed
in unsynchronized cultures. A culture in G2-
mitosis, i.e. 8 hr after removal of thymidine, when
treated with this dose of AMD shows no cell
killing at 6 hr and only 50% at 12 hr . When this
dose of AMD is administered to HeLa cultures
held in the second thymidine block, i.e. the HeLa
cultures kept in thymidine-containing medium
before, during, and after AMD exposure, 65'/' o
of the culture is killed by 6 hr, and less than 1 %
of the original cell number remains attached to
the surface of the flask by 12 hr . Since cells held in
the second thymidine block are near the beginning
of S (G1-S interphase) and DNA synthesis is
virtually completely inhibited, HeLa cells need
not be actively synthesizing DNA to be susceptible
to AMD while in S . In contrast to HeLa cells,
thymidine-synchronized Vero cultures exposed
to AMD (10 µg/ml given continuously) while in
the second thymidine block, or while in G 2-mitosis,
i.e. 10 hr after removal of thymidine, do not show
any difference in the number of cells killed before
24 hr as compared to unsynchronized cultures
treated with the same dose (Table IV) .
HeLa or Vero monolayers were synchronized with excess thymidine and then treated
with AMD (HeLa, 2 .5 µg/m1 for 1 hr ; Vero, 10 µg/ml continuously) either during the
TdR blockade, 2 hr after removal of TdR (S phase), or 8 hr after removal of TdR
(G2-M phase). The number of living cells was determined at 6, 12, and 48 hr and is
expressed as per cent of the initial cell number .
TABLE V
Effect of Hydroxyurea, Actinomycin D, or Hydroxy-
urea and Actinomycin D on the Number of Viable
HeLa Cells
µg/ml) and hydroxy-
urea (25 mm)
HeLa cells were exposed for 24 hr to hydroxyurea
(25 mm), actinomycin D (0.1 µg/ml), or hydroxy-
urea (25 mm) and actinomycin D (0.1 µg/ml), and
the viable cells were counted at 6, 12, and 24 hr.
The results are expressed as per cent of the 0 hr cell
number.
Another indication that inhibition of DNA
synthesis per se does not cause cell degeneration is
afforded by the following experiment. HeLa cells
in exponential growth were exposed to 25 mm
hydroxyurea in the presence or absence of 0 .1
jug/ml of AMD. Table V shows that this concentra-
tion of hydroxyurea, which completely and im-
mediately inhibits DNA synthesis, does not cause
a significant loss of HeLa cells for 24 hr . When
the hydroxyurea is given to HeLa cells in the
presence of 0.1 ug/ml of AMD, there is an equiva-
lent loss of cells as compared to that observed after
the same concentration of AMD given alone
(0.1 µg/ml for 24 hr) . Hence, the early acute cyto-
toxicity of AMD observed in HeLa cells is not
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6 hr
	
12 hr
	
24 hr
HeLa Vero HeLa Vero HeLa Vero
No TdR (asynchronous) 85 100 25 90 <15 85
Continuous
aded)
TdR (block- 34 100 < 5 90 ~-_Z0 85
S phase 54 10 <1
G2-M phase 100 100 50 90 40 85
6 hr 12 he 24 he
Hydroxyurea (25 mM) 105 110 98
Actinomycin D (0.10
µg/ml)
98 70 3
Actinomycin D (0.10 95 55 3due to the inhibition of DNA synthesis, but is
nevertheless somehow related to the cell cycle .
DISCUSSION
We have shown that HeLa cells are killed during
an early rapid cytotoxic phase after exposure to
AMD, i.e. after 3-12 hr, whereas most cell types
such as Vero, W138, or L cells, treated with com-
parable or higher doses of AMD, are not suscep-
tible to an early phase of lethality, but only after
1-3 days does a gradual loss of these cells occur.
Since AMD inhibits transcription as effectively in
Vero, W138, or L cells as in HeLa cells, and since
the amount of acute killing in HeLa cells is pro-
portional to the dose after depression of 85%
of RNA synthesis, the acute cytotoxicity of AMD
might not at first appear to be an immediate con-
sequence of the inhibition of RNA synthesis per
se. Such a conclusion had been reached by Sch-
wartz and his collaborators (44) on the basis of
comparative studies of different tissues and tumors
of animals. However, the toxicity of AMD, and
that of analogous DNA-binding RNA synthesis
inhibitors, is dependent upon their ability to
suppress RNA synthesis.
RNA Synthesis
Only doses of AMD sufficient to inhibit RNA
synthesis almost completely in HeLa cells bring
about acute cytotoxicity in which 75-80% of the
viable cells are lost within 12 hr. Only HeLa cells
of the several lines observed succumb in this way .
Concentrations of AMD that partially block RNA
formation are known to inhibit preferentially the
production of ribosomal RNA while permitting
the continued synthesis of other species of RNA
(12, 28, 37). That acute killing of HeLa cells might
be due to the loss of some critical species of non-
ribosomal RNA whose synthesis is inhibited only at
higher concentrations of AMD is suggested by :
(a) the 2.5-3 hr latent period between the addi-
tion of AMD and the onset of acute cell death,
and (b) the occurrence of acute lethality only
after 85% 0 of over-all RNA synthesis has been
inhibited. Doses that almost immediately and
completely inhibit RNA synthesis do not shorten
the latent period before acute killing; however,
lower doses of AMD that inhibit RNA synthesis
at a slower rate cause a proportional delay in the
onset of the acutely lethal phase . Furthermore, the
other inhibitors of RNA synthesis, daunomycin
and nogalamycin, cause a similar phase of acute
756
	
THE JOURNAL OF CELL BIOLOGY • VOLUME 50, 1971
cell death in HeLa cells. If a species of RNA with
a short natural half-life, or one subject to degrada-
tion after AMD, is vital to HeLa cells, it must be
assumed to function in some manner other than
in the production of protein(s) . The virtually com-
plete inhibition of protein synthesis by strepto-
vitacin A does not cause early acute injury in HeLa
cells as does inhibition of RNA synthesis . Various
species of RNA of unknown function, either con-
fined to the nucleus (1, 7, 17, 26, 34, 39, 52, 53) or
in the cytoplasm (27), have been identified . Cer-
tain of these RNA species may function in some
unknown manner, perhaps not directly related to
protein synthesis, and their decay results in the
acute degeneration of cells.
Actinomycin D and other inhibitors of RNA syn-
thesis, at concentrations in excess of those that
inhibit RNA synthesis, do not cause acute cell
death in Vero, WI38, or L cells, although Vero
and L cells divide (and probably synthesize RNA)
at an approximately similar rate, and are main-
tained under the same conditions as HeLa cells.
Certain differences must exist among cell types
which would account for the selective susceptibility
of HeLa cells to acute cyto-intoxication induced by
inhibitors of RNA synthesis. If HeLa cells require
the continued synthesis of certain "critical" species
of RNA, then these cell types either do not re-
quire these RNA species or have them in a more
stable, or longer lived, form. That Vero cells might
possess similar, except more stable, species of RNA
whose existence is vital to cells is suggested by the
data of Fig. 3 and Table I. Although RNA syn-
thesis is completely inhibited in Vero cells fol-
lowing a 1 hr exposure to 10 µg/ml of AMD, it
returns promptly after drug removal (Table I)
and almost no cells are lost from the culture (Fig .
3). On the other hand, Vero cells given 10 .sg/ml
(or lower concentrations) of AMD for 24 hr be-
come moribund between 48 and 72 hr (Fig. 3).
Therefore, susceptibility and relative resistance to
AMD-induced acute lethality among various types
of cultured cells might be due to the presence of
critical species of RNA, short-lived in some cell
types, longer lived in others . If RNA synthesis is
suppressed for long periods, all cell types even-
tually succumb to continued AMD poisoning, but
some, e.g. HeLa cells, intestinal epithelium (44),
avian myeloblasts (55), and KB and chick em-
bryo cells (35), are killed much sooner than
others.RNA Degradation
Following the administration of AMD there is
a significant loss of RNA, the bulk of which con-
sists of the newly synthesized, rapidly labeled RNA
of the nucleus (15, 17, 27, 40, 41, 47, 52, 53) .
This loss of RNA after AMD probably represents
the unmasking of a physiologically normal decay
of the so-called nuclear heterodisperse RNA (17,
27, 48, 52), but it may perhaps also be due, at
least in part, to an abnormally induced degrada-
tion of newly synthesized RNA (38, 49) . This
decay and depletion of RNA after AMD have
been implicated by some as a mechanism causing
late cell death (42, 44, 54). However, the marked
susceptibility of HeLa cells to early lethal injury
cannot be demonstrably associated with a gross
loss or breakdown of RNA during the first 3-4 hr.
RNA depletion of nearly the same magnitude
occurs in HeLa cells treated with a wide range of
drug concentrations (0.05-5.0µg/ml), all of which
reduce RNA synthesis by at least 50 % by I hr,
in contrast to the strict dose dependence of acute
lethality at these concentrations ; furthermore,
Vero and W138 cells lose equivalent amounts of
prelabeled RNA as HeLa during the first 3-4 hr,
without suffering acute degeneration.
Inhibition of Protein Synthesis
Since the nearly complete and immediate in-
hibition of protein synthesis by streptovitacin A
does not cause early acute lethal injury in HeLa
cells, the eventual partial inhibition of protein
synthesis by AMD would not appear to be a
direct cause of acute cell death. In the interval
under consideration, since protein synthesis is only
partly inhibited (by about 50%), there must be
some imbalance in both the amounts and kinds of
proteins being accumulated. Moreover, it is known
that in some circumstances AMD can "paradox-
ically" stimulate the formation, i .e. translation,
of certain proteins (chiefly enzymes) whose rela-
tively stable messages have been released from
translational repression (51). It is, therefore, at
least theoretically possible to envisage the accumu-
lation of abnormal amounts and/or kinds of poly-
peptides which might be toxic. This eventuality
is unlikely because the simultaneous inhibition of
protein synthesis and RNA synthesis by the com-
bined administration of streptovitacin A and AMD
does not protect HeLa cells but actually aug-
ments the acute cytotoxicity of AMD . Nor does
hibition of protein synthesis protect cells against
the ultimate lethal effects of AMD as measured
by reproductive survival analysis (8) as it does
against irradiation (32), or the lethal effects of
cytosine arabinoside (20) or mitomycin C (8).
Inhibition of DNA Synthesis and the
Cell Cycle
Actinomycin D at high concentrations directly
affects DNA synthesis (2, 22, 35) ; it has been
argued that the toxic mechanism of AMD is
related, at least in some part, to inhibition of DNA
synthesis (2, 43). Schwartz et al. (43) attempted to
correlate early acute injury of intestinal epithelial
cells after AMD with inhibition of DNA synthesis
rather than with inhibition of RNA synthesis,
because RNA synthesis appears to be only mod-
erately affected in these cells after cytotoxic
doses of AMD while DNA synthesis is suppressed,
and because inhibitors of DNA synthesis cause
similar acute injury in the same cells. However,
Farber and Baserga (Il) have shown that in-
hibition of DNA synthesis per se is not sufficient
to cause acute injury since proliferating cells other
than intestine are not susceptible to fatal acute
poisoning by inhibitors of DNA synthesis . Direct
and complete inhibition of DNA synthesis by ex-
cess thymidine (10 mm) or hydroxuyrea (25 mm)
does not cause acute damage to HeLa cells such
as occurs in certain proliferating cell popula-
tions of animals given hydroxyurea (31) . More-
over, the simultaneous exposure of HeLa cells to
AMD and hydroxyurea does not significantly
alter either the time of first occurrence or the
rate of cell degeneration from that observed
after exposure to an equal dose of AMD. Thus, al-
though HeLa cells appear analogous to intestinal
epithelial cells in sensitivity to the acute cytotoxi-
city of AMD, they do not exhibit a similar sensi-
tivity to inhibitors of DNA synthesis .
Although HeLa cells in S are more susceptible
to the acute cytotoxicity of AMD than cells in G 2 ,
cells blocked with excess thymidine, i.e. at or
near the G1-S interphase, are destroyed even more
rapidly by AMD than cells treated while actively
synthesizing DNA. For this and other reasons, it
appears that cells need not progress to a certain
stage of the division cycle in order for the damage
to be expressed. All HeLa cells, regardless of their
position in the division cycle, if treated with suf-
ficiently high doses of AMD die within several
hours. Only at lower doses of AMD does a pref-
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757erential killing of cells at the G1-S interphase or
of cells in S occur. Since HeLa cells increase their
rate of RNA synthesis as they initiate DNA syn-
thesis (30), the increased sensitivity to inhibitors of
RNA synthesis during or immediately preceding
DNA synthesis may reflect a critical requirement
for RNA synthesis at this phase of the division
cycle. A more probable hypothesis is that as the
rate of RNA synthesis increases during late G, or
early S, the DNA in chromatin may serve as a
better binding site for AMD, resulting in height-
ened sensitivity to inhibitors of RNA synthesis that
bind to DNA. Acceleration of RNA synthesis in
lymphocytes stimulated with phytohemagglutinin
has been shown to be paralleled by an increased
ability of chromatin to bind AMD (4, 5) . Lower
concentrations of AMD might more effectively
inhibit RNA synthesis at certain stages of the
division cycle due to increased availability of bind-
ing sites. Cells in G,-S or in S are apparently more
vulnerable to disturbances in biosynthesis of nucleic
acids or proteins (23), but certain cell types are
obviously more susceptible to these perturbations .
As another instance of the variation among cell
types in response to the same drug, Pfeiffer and
Tolmach (29) have shown that HeLa cells are able
to withstand up to 19 hr of exposure to hydroxyurea
without any lethal effects while Chinese hamster
cells in S are killed during a 1 hr exposure (46) .
Actinomycin Uptake and Retention
Susceptibility of HeLa cells to early acute in-
jury as compared to Vero, W138, or L cells is
not strictly dependent on differential uptake or
retention of AMD among these cell types. Al-
though HeLa cells bind more AMD14C at a
given dose, the other cell types given higher doses
can bind as much or more AMD without succumb-
ing to acute cytotoxicity. Furthermore, HeLa cells
in G2 bind as much or more AMD14C as cells in
S, although cells in S are more susceptible to early
fatal injury.
The results of our study show that Vero cells,
as compared to HeLa, W138, or L cells, are able
to rapidly release and excrete AMD, which is
promptly followed by reinstatement of RNA
synthesis. However, Vero cells do not recover their
capacity for cell division until 2 days or more after
exposure to pulse doses of AMD. This ability to
excrete bound AMD and to resume RNA syn-
thesis quickly after removal of AMD from the
medium enables Vero cells to recover after a I
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hr exposure to very high concentrations of AMD
which would destroy other cell types. Vero cells
thus appear to be analogous to liver cells with
respect to their low retentiveness of AMD and
their relative insusceptibility to its toxic effects
(44).
Binding of AMD by DNA is a necessary condi-
tion for cytotoxicity as well as for inhibition of
transcription. Exposure of HeLa cells to the non-
binding derivative deamino-actinomycin C 2 (10
yg/ml) did not result in acute killing in our ex-
periments, nor does it affect the growth of HeLa
cells (36). Other studies (2, 8-10, 13, 23) have
drawn attention to the similarity in the shapes of
dose-response curves of reproductive survival after
AMD and after ionizing radiation or radiomimetic
drugs. Some of these investigators (8, 9) have com-
mented on the additive interaction of these agents,
and on the similar "age" dependence of their
dose-response curves, and have suggested that the
toxic effects of both AMD and irradiation depend
upon the interaction of each with DNA, but that
they are not entirely the same.
Recovery
The ability or inability of cells to recover after
AMD may reflect a cytoplasmic state caused by
AMD, similar to that of mature hen erythrocytes
which lack certain cytoplasmic or nuclear factors
capable of initiating nuclear activity, but which
factors are present in cells capable of division (16).
This possibility gains credence from the experi-
ment of Lorch and Jeons (21) who interchanged
the nuclei and cytoplasms of AMD-treated and
untreated amebae. Amebae reconsituted from
AMD-treated nuclei and untreated cytoplasm
recovered nuclear activity and became reproduc-
tive. Insertion of untreated nuclei into the cyto-
plasm of previously treated amebae, however,
resulted in a loss of nuclear activity and of re-
productive capacity. The stability or presence of
cytoplasmic factors involved in the initiation of
nuclear activity varies with different types of cells
and throughout the cell cycle (6, 33, 50) . As AMD
diffuses out of Vero cells these factors, which might
be longer lived or more stable in Vero, would con-
tribute to the reinitiation of RNA synthesis and
reproductive recovery. Other cell types, however,
like W138, although they do not bind as much
AMD and eliminate much of what is bound, do
not recover RNA synthesis, perhaps due to the
more rapid physiological decay of and failure to re-plenish these cytoplasmic factors. This might serve
to explain the selective susceptibility or resistance
of certain animal tumors to chemotherapy with
AMD.
In conclusion, we have demonstrated that AMD
induces in HeLa cells an early acute degenerative
process, similar to that observed in intestinal
epithelial cells, which does not occur until much
later in most other cell types. Other inhibitors of
RNA synthesis initiate a similar phase of early
injury in HeLa cells, while inhibitors of DNA or
protein synthesis do not . For these and other
reasons, we suggest that cells may require certain
species of RNA that are lost rapidly from HeLa
cells but more slowly from other cell types fol-
lowing inhibition of RNA synthesis and which are
vital for maintaining cellular integrity . The dif-
ferences in response of different cell types or of cells
in different stages of the division cycle to inhibition
of transcription may be due to differences in the
quality, function or stability of the RNA species
whose synthesis is suppressed . These species of
RNA would not appear to function directly in
protein synthesis and probably represent only a
small fraction of the total nonribosomal RNA of
cells. This possibility might be examined by cen-
trifugational and electrophoretic analysis of the
various species of nonribosomal RNA from dif-
ferent types of cells after inhibition of RNA
synthesis, and their rates of decay.
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